FDA Expands PALYNZIQ Approval to Adolescents with PKU
Event summary
- FDA approved BioMarin's PALYNZIQ for adolescents aged 12+ with PKU on February 27, 2026.
- Approval based on Phase 3 PEGASUS study showing significant blood Phe reduction vs. diet alone.
- PALYNZIQ is the only genotype-independent enzyme substitution therapy for PKU.
- Company seeks similar approval from European Medicines Agency.
The big picture
This FDA approval extends BioMarin's PALYNZIQ to a younger demographic, addressing a critical gap in PKU management during adolescence. The expansion reflects growing demand for genotype-independent therapies that reduce dietary restrictions. BioMarin's strategic focus on rare disease treatments positions it to capture a larger share of the PKU market, particularly as it pursues similar approvals in other regions.
What we're watching
- Market Expansion
- Whether BioMarin can successfully expand PALYNZIQ's market reach to European adolescents.
- Adoption Rates
- The pace at which adolescents with PKU adopt PALYNZIQ given its safety profile.
- Competitive Position
- How this approval strengthens BioMarin's leadership in PKU treatments.
Related topics